Closing Mexico's Rare Disease Diagnostic Gap: A Strategic Imperative for Healthcare Transformation

An estimated 8 to 10 million people in Mexico live with a rare disease, yet the vast majority navigate a fragmented healthcare system that struggles to recognize their conditions. Each delayed diagnosis translates into years of suffering, preventable complications, and inefficient use of healthcare resources. Closing this diagnostic gap, experts argue, is both an ethical responsibility and a strategic decision for the country's health system.

The scale of the challenge is immense. While each rare disease affects a relatively small number of individuals—defined generally as fewer than one in 2,000 people—collectively these conditions represent a major public health burden. According to estimates based on international prevalence applied to Mexico's population, between 8 and 10 million Mexicans are affected. Behind these numbers lie shared experiences: misdiagnoses, long journeys through multiple clinics, ineffective treatments, and preventable complications.

The Diagnostic Odyssey and Its Toll

International experience shows that patients with rare diseases (search)Search disease can wait five to seven years on average before receiving an accurate diagnosis. In Mexico, available evidence suggests similar or even longer trajectories. During this period, individuals see multiple specialists and receive treatments that fail to help—sometimes even worsening their condition or producing secondary effects.

For the healthcare system, this translates into avoidable hospitalizations, repeated use of general tests without clear rationale, and rising costs without proportional results. For families, the consequences include loss of productivity, catastrophic out-of-pocket expenses, and significant psychological distress.

This odyssey is exacerbated by well-documented structural gaps. Mexico has few tertiary-level centers capable of managing these diseases, and standardized protocols for suspicion and referral are lacking. The health system's fragmentation—with multiple public and private subsystems including IMSS, ISSSTE, PEMEX, SEDENA, SEMAR, and state healthcare systems—produces highly uneven and often labyrinthine care pathways. Timely diagnosis becomes a privilege tied to geography, socioeconomic status, or access to tertiary medical attention, rather than a basic standard of care.

Structural Barriers at Multiple Levels

Primary care physicians in public settings frequently lack the tools and time to consider rare diseases (search)Search disease among their differential diagnoses, with extremely limited consultation time per patient. Clear referral and counter-referral routes to accelerate evaluation of suspected cases remain absent. This is compounded by limited availability of high-complexity testing, such as genomic panels, meaning advanced diagnostics are used infrequently or too late.

Mexico also lacks a comprehensive national registry of rare diseases (search)Search disease. Without systematic data, policymakers cannot fully comprehend the problem, plan resources, or evaluate public policies. The absence of information complicates everything from strategic procurement of diagnostic inputs to the design of clinical pathways.

Genomics as a Central Solution

Approximately 80% of rare diseases (search)Search disease have a genetic basis, making genomics a central tool for shortening the diagnostic odyssey. Mexico already possesses scientific and technological capabilities in genomics, high-level research centers, and skilled professionals capable of interpreting complex data.

The Instituto Nacional de Medicina Genómica (INMEGEN) (search)Search term, under the leadership of General Director Jorge Meléndez Zajgla, has the largest experience in genomic diagnosis for rare diseases (search)Search disease in the country, performing more than a thousand tests each year. "Mexico is at a point where its scientific capacity, innovation ecosystem and growing interest in precision medicine can align to advance to the Medicine that the country will require in the next few years," Meléndez Zajgla notes.

Additional opportunities include developing diagnostic reference centers, specialized laboratories, and clinical decision-support platforms. These could range from multigene panels tailored to Mexico's population profile to digital tools integrating clinical and genomic data—such as the Iniciativa Mexicana para la Oncogenómica Pediátrica (IMOP)—to guide physicians toward more precise diagnoses.

The Role of Public-Private Partnerships

Transforming rare disease diagnosis requires collaboration between sectors. The public sector can contribute scale, legitimacy, and an equity-driven vision for access, while the private sector brings capital, innovation, deployment capabilities, and agile execution. A first step could involve designing collaborative schemes to implement pilot genomic diagnostic programs for rare diseases (search)Search disease, demonstrating cost-effectiveness and feasibility before scaling nationwide.

For the private sector, this opens space to offer evidence-based solutions with payment models built around value and outcomes, potentially aligning incentives with shorter time-to-diagnosis or decreased overall costs across a patient's life.

Legislative Momentum and Institutional Progress

Recent years have brought encouraging signs. In 2023, the Consejo de Salubridad General (search)Search term issued an Agreement to recognize rare diseases (search)Search disease following WHO guidelines. Legislative initiatives in the Chamber of Deputies seek to amend the General Health Law to create both a National Commission of Rare Diseases and a National Registry of Rare Diseases, accompanied by a dedicated chapter formally defining these conditions and mandating comprehensive care.

Parallel proposals in the Senate reinforce the State's responsibility for rare diseases (search)Search disease and call for stronger institutional architecture to support diagnosis, treatment, and long-term follow-up. These efforts gained visibility in February 2026 during the First Bicameral National Forum on Rare Diseases, where deputies and senators backed the creation of the Registry and the Commission and advocated for early diagnosis and a specific Health Fund for Rare Diseases.

Both INMEGEN and UNAMView company profile have already launched patient registries, and INMEGEN has established a diagnostic program for rare diseases (search)Search disease. These success stories demonstrate that combining scientific capacity, institutional commitment, and collaboration can produce tangible impact.

The Path Forward

The central challenge remains scaling these experiences into coordinated policy. Priorities include updating and expanding the official list of rare diseases (search)Search disease, strengthening a unified national registry, and defining explicit diagnostic pathways that include criteria for advanced testing. Payers—both public institutions and private insurers—can adopt coverage schemes for high-complexity diagnostics, particularly when evidence shows these tests prevent years of inefficient care.

National Health Institutes play an irreplaceable role in generating local evidence. Estimating the true cost of a diagnostic odyssey, comparing scenarios with and without access to advanced testing, and documenting the clinical and economic benefits of early diagnosis are essential steps. With such data, decisions on financing and prioritization move from abstract discussion to informed public policy choices grounded in humane distributive justice.

As Meléndez Zajgla emphasizes: "Without a diagnosis, there is no treatment, no planning, and no real assessment of cost effectiveness. Investing in timely diagnosis of rare diseases (search)Search disease is not a luxury. It is a smart strategy to organize the system, protect patients, and use available resources more efficiently."